A Study of DNL310 in Pediatric Participants With Hunter Syndrome
study id #: NCT04251026
condition: Mucopolysaccharidosis II
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL310, an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).
The study has three cohorts:Cohort A will enroll participants with neuronopathic MPS II aged 5 to 10 years; Cohort B will enroll participants with MPS II, either neuronopathic or non-neuronopathic, aged 2 to 18 years; and Cohort C will enroll participants with neuronopathic MPS II aged ≥2 and <4 (Cohort C can include nMPS II participants ≥4 if the participant is a sibling of a participant aged ≥2 and <4).
Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension for continued evaluation.
last updated: February 26, 2022
start date: July 16, 2020
estimated completion: March 2024
last updated: January 11, 2022
phase of development: Phase 1/Phase 2
size / enrollment: 30
- Incidence and severity of treatment-emergent adverse events (TEAEs)
- 24 weeks
Incidence and severity of infusion-related reactions (IRRs)
- 24 weeks
Change from baseline in urine total glycosaminoglycan (GAG) concentrations
- 24 weeks
Change from baseline in concomitant medications
- 24 weeks
- Change from baseline in cerebrospinal fluid (CSF) of heparan sulfate
- PK parameter: Maximum observed concentration (Cmax) of DNL310 in serum
- PK parameter: Trough concentration (Cmin) of DNL310 in serum
- PK parameter: Time to maximum observed concentration (tmax) of DNL310 in serum
- PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of DNL310 in serum
- PK parameter: Area under the concentration-time curve from time zero to infinity (AUC∞) of DNL310 in serum
- PK parameter: Area under the concentration-time curve over a dosing interval (AUCτ) of DNL310 in serum
- PK parameter: Apparent terminal elimination half-life (t½) of DNL310 in serum
- Characterization of immunogenicity of DNL310 in serum, as measured by the incidence of anti-drug antibodies (ADAs) relative to baseline
- Change from baseline in urine concentration of heparan sulfate (HS)
• Eligible Sexes: male
Confirmed diagnosis of MPS II
Cohort A: Participants aged 5 to 10 years with neuronopathic MPS II
Cohort B: Participants aged 2 to 18 years with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype
Cohort C: Participants aged ≥2 to <4 years with neuronopathic MPS II (this cohort can include participants ≥4 years of age if participant is a sibling of a participant ≥2 to <4 years of age)
For participants receiving intravenous iduronate 2-sulfatase (IDS) ERT, tolerated a minimum of 4 months of therapy during the period immediately prior to screening.
exclusion criteria: Criteria:
Unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
Use of any CNS-targeted MPS II ERT within 3 months before study start for participants aged ≥5 years, and within 6 months before study start for participants aged <5 years.
Use of IDS gene therapy or stem cell therapy at any time
Clinically significant thrombocytopenia, other clinically significant coagulation abnormality, or significant active bleeding, or required treatment with an anticoagulant or more than two antiplatelet agents
Contraindication for lumbar punctures
Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any CNS disease that is not MPS II-related within 1 year of screening
Have had a ventriculoperitoneal (VP) shunt placed, or any other brain surgery, or have a clinically significant VP shunt malfunction within 30 days of screening
Have any clinically significant CNS trauma or disorder that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe
sponsor: Denali Therapeutics Inc.
contacts: Clinical Trials At Denali Therapeutics, Email:, email@example.com
investigators: Anna Bakardjiev, MD,Denali Therapeutics
trial center locations: United States,Netherlands
United States, California
UCSF Benioff Children’s Hospital
Esther Melton, 510-428-3885, firstname.lastname@example.org
United States, Illinois
Ann & Robert H. Lurie Children’s Hospital of Chicago
Marian Krasowski, 312-227-8953, email@example.com
United States, North Carolina
UNC Children’s Research Institue
Chen Zhu, 919-966-1447, firstname.lastname@example.org
United States, Pennsylvania
UPMC | Children’s Hospital of Pittsburgh
Dawn Kolar, 412-692-8343, email@example.com
Netherlands, South Holland
Erasmus Medical Center
Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis Type IMusculoskeletal findings in MPS can prog...
MPSBase: Comprehensive Repository of Differentially Expressed Genes for MucopolysaccharidosesMucopolysaccharidoses (MPS) are lysosoma...
Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and GlycosaminoglycansMucopolysaccharidoses (MPS) and mucolipi...
Macular Changes in a Mucopolysaccharidosis Type I Patient With Earlier Systemic TherapiesTo describe retinal findings in a patien...
Molecular Characterization of a Large Cohort of Mucopolysaccharidosis Patients: Iran Mucopolysaccharidosis Re-Diagno...Mucopolysaccharidoses (MPSs) are rare, h...
Production of Therapeutic Iduronate-2-Sulfatase Enzyme With a Novel Single-Stranded RNA Virus VectorThe Sendai virus vector has received a l...
Evaluation of the Long-Term Treatment Effects of Intravenous Idursulfase in Patients With Mucopolysaccharidosis II (...Mucopolysaccharidosis II (MPS II; Hunter...